| Literature DB >> 29335491 |
Chenyan Zhao1, Chao Ding1,2, Tingbin Xie1, Tenghui Zhang1, Xujie Dai1, Yao Wei1, Yi Li1, Jianfeng Gong3, Weiming Zhu4.
Abstract
Systemic Inflammation-Based modified Glasgow Prognostic Score (mGPS) was developed as an objective tool to grade state of inflammation. However, the association between mGPS and postoperative complications for inflammatory bowel disease (IBD) patients was still unknown. In our study, 270 IBD patients [Crohn's disease (CD), n = 186; Ulcerative colitis (UC), n = 84] from January 2013 and January 2016 who underwent elective bowel resection were retrospectively analyzed, and, the levels of preoperative C-reactive protein (CRP) and albumin were included as parameters of mGPS. The incidence of overall postoperative complications was 44.81% (121/270), including 46.77% (87/186) of CD and 40.48% (34/84) of UC. According to multivariate analysis, mGPS (CD: OR = 3.47, p = 0.003; UC: OR = 3.28, p = 0.019) was independently associated with an increased risk of postoperative complications. Patients with a higher mGPS also suffered longer postoperative stay and increased SSIs (both p < 0.05). Combining mGPS with neutrophil ratio improved its prognostic value with a better area under the curve (AUC), using receiver operating characteristic (ROC) method. Then we confirmed that mGPS was associated with postoperative complications in IBD patients undergoing elective bowel resection and the addition of neutrophil ratio enhanced its prognostic value.Entities:
Mesh:
Year: 2018 PMID: 29335491 PMCID: PMC5768763 DOI: 10.1038/s41598-017-18771-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Systemic Inflammation-Based Prognostic Scores.
| Points Allocated | |
|---|---|
| Modified GPS (mGPS) | |
| CRP ≤ 10 mg/L and albumin ≥ 35 g/L | 0 |
| CRP >10 mg/L | 1 |
| CRP >10 mg/L and albumin <35 g/L | 2 |
| GPS = Glasgow Prognostic Score; CRP = C-reactive protein. | |
Figure 1The distribution of IBD patients across the mGPS. CD, Crohn’s disease; UC, Ulcerative colitis; mGPS, modified Glasgow Prognostic Score.
Univariate Analysis of Baseline Factors associated with Postoperative Complications.
| Group | All (n = 270) | CD (n = 186) | UC (n = 84) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Non-complications | Complications | P | Non-complications | Complications | P | Non-complications | Complications | P | |
| No. of patients | 149 | 121 | 99 | 87 | 50 | 34 | |||
| Age, years* | 34.38 ± 11.41 | 37.83 ± 13.51 | 0.024 | 34.56 ± 10.55 | 36.13 ± 12.29 | 0.349 | 34.04 ± 13.07 | 42.18 ± 15.58 | 0.011 |
| Sex, male† | 76 (51.00%) | 81 (66.94%) | 0.008 | 57 (57.58%) | 61 (61.62%) | 0.076 | 19 (38.00%) | 20 (58.82%) | 0.060 |
| BMI (kg/m2)* | 18.28 ± 2.09 | 18.30 ± 2.76 | 0.943 | 17.68 ± 1.93 | 17.93 ± 2.29 | 0.398 | 19.47 ± 1.88 | 19.22 ± 3.60 | 0.681 |
| Disease duration before admission, years* | 6.03 ± 6.24 | 5.63 ± 5.36 | 0.581 | 6.11 ± 4.08 | 5.54 ± 4.13 | 0.345 | 5.87 ± 9.18 | 5.88 ± 7.75 | 0.998 |
| Smoke within 3 months† | 3 (2.01%) | 8 (6.61%) | 0.057 | 2 (2.02%) | 4 (4.60%) | 0.321 | 2 (4.00%) | 3 (8.82%) | 0.163 |
| mGPS* | 0.46 ± 0.64 | 1.02 ± 0.81 | <0.001 | 0.37 ± 0.58 | 0.86 ± 0.79 | <0.001 | 0.64 ± 0.72 | 1.44 ± 0.70 | <0.001 |
| CRP >10 mg/L (1 day before surgery)† | 32 (21.48%) | 62 (51.24%) | <0.001 | 11 (11.11%) | 37 (42.53%) | <0.001 | 21 (42.00%) | 25 (73.53%) | 0.004 |
| Albumin <35 g/L (1 day before surgery)† | 38 (25.50%) | 60 (49.59%) | <0.001 | 27 (27.27%) | 36 (41.38%) | 0.043 | 11 (22.00%) | 24 (70.59%) | <0.001 |
| Neutrophil ratio >75% (1 day before surgery)† | 13 (8.70%) | 33 (27.27%) | <0.001 | 7 (7.07%) | 18 (20.69%) | 0.007 | 6 (12.00%) | 15 (44.12%) | 0.001 |
| Hemoglobin <12 g/dL (1 day before surgery)† | 56 (37.58%) | 67 (55.37%) | 0.004 | 29 (29.29%) | 43 (49.43%) | 0.005 | 27 (54.00%) | 24 (70.59%) | 0.127 |
| Platelet >400 × 109/L (1 day before surgery)† | 22 (14.77%) | 35 (28.93%) | 0.005 | 10 (10.10%) | 15 (17.24%) | 0.154 | 12 (24.00%) | 20 (58.82%) | 0.001 |
| Preoperative treatment† | |||||||||
| 5-ASA | 5 (3.36%) | 10 (8.26%) | 0.080 | 4 (4.04%) | 8 (9.20%) | 0.153 | 1 (2.00%) | 2 (5.88%) | 0.347 |
| Preoperative steroids for ≥ 3 months | 6 (4.03%) | 30 (24.79%) | <0.001 | 2 (2.02%) | 11 (12.64%) | 0.007 | 4 (8.00%) | 19 (55.88%) | <0.001 |
| Immunosuppressant | 31 (20.81%) | 35 (28.93%) | 0.123 | 25 (25.25%) | 29 (33.33%) | 0.226 | 6 (12.00%) | 6 (17.65%) | 0.468 |
| Infliximab | 17 (7.38%) | 22 (23.14%) | 0.115 | 5 (5.05%) | 9 (10.34%) | 0.172 | 12 (24.00%) | 13 (38.24%) | 0.161 |
| Enteral nutrition | 115 (77.18%) | 94 (77.69%) | 0.921 | 89 (100%) | 70 (80.46%) | 0.068 | 24 (70.59%) | 26 (52.00%) | 0.088 |
| Parenteral nutrition | 36 (24.16%) | 35 (28.93%) | 0.376 | 24 (24.24%) | 22 (25.29%) | 0.869 | 12 (24.00%) | 13 (38.24%) | 0.161 |
| Type of surgery† | |||||||||
| Total colectomy | 12 (8.05%) | 23 (19.01%) | 0.008 | 7 (7.07%) | 15 (17.24%) | 0.032 | 5 (10.00%) | 8 (23.53%) | 0.095 |
| Segmental colectomy | 22 (14.77%) | 29 (23.97%) | 0.055 | 20 (20.20) | 25 (28.74%) | 0.175 | 2 (4.00%) | 4 (11.76%) | 0.216 |
| IPAA | 43 (86.00%) | 22 (64.71%) | 0.033 | — | — | — | 43 (86.00%) | 22 (64.71%) | 0.033 |
| Ileocecal resection | 29 (19.46%) | 18 (13.95%) | 0.323 | 29 (29.29%) | 18 (20.69%) | 0.178 | — | — | — |
| Small bowel resection | 41 (27.52%) | 31 (25.62%) | 0.726 | 41 (41.41%) | 31 (35.63%) | 0.419 | — | — | — |
| Operation details† | |||||||||
| First time operation | 105 (70.46%) | 78 (64.46%) | 0.598 | 69 (69.70%) | 46 (52.87%) | 0.018 | 38 (76.00%) | 30 (88.24%) | 0.257 |
| Laparoscopic completed cases | 76 (51.01%) | 49 (40.50%) | 0.085 | 26 (26.26%) | 18 (20.69%) | 0.372 | 50 (100.00%) | 31 (91.18%) | 0.649 |
| Operative time >180 min | 83 (55.70%) | 64 (52.89%) | 0.645 | 33 (66.67%) | 30 (34.48%) | 0.869 | 50 (100.00%) | 34 (100.00%) | — |
| Blood loss, ml | 89.97 ± 63.59 | 93.51 ± 68.59 | 0.660 | 101.21 ± 73.86 | 104.43 ± 74.17 | 0.768 | 67.70 ± 23.24 | 65.59 ± 40.67 | 0.763 |
| Stoma | 78 (52.35%) | 52 (42.98%) | 0.125 | 28 (28.28%) | 18 (20.69%) | 0.231 | 50 (100.00%) | 34 (100.00%) | — |
CD = crohn’s disease; UC = ulcerative colitis; BMI = body mass index; mGPS = modified Glasgow Prognostic Score; CRP = C-reactive protein; 5-ASA = 5-aminosalicylic acid; IPAA = ileal pouch-anal anastomosis.
*Values are expressed as the mean ± SD; †values are expressed as n (%).
Multivariate Analyses of Factors associated with Postoperative Complications.
| CD | UC | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| p | OR | 95% CI | p | p | OR | 95% CI | p | |
| Age, years | 0.349 | 0.011 | 1.103 | 0.905–1.137 | 0.994 | |||
| Sex, male | 0.076 | 1.261 | 1.024–2.533 | 0.224 | 0.060 | 1.376 | 0.989–1.719 | 0.161 |
| mGPS (0/1/2) | <0.001 | 3.473 | 1.107–5.330 | 0.003 | <0.001 | 3.275 | 1.639–3.784 | 0.019 |
| Neutrophil ratio >75% (1 day before surgery) | 0.007 | 1.922 | 1.058–2.491 | 0.027 | 0.001 | 2.265 | 1.788–2.794 | 0.031 |
| Hemoglobin <12 g/dL (1 day before surgery) | 0.005 | 1.354 | 0.756–1.945 | 0.126 | 0.127 | — | — | — |
| Platelet >400 × 109/L (1 day before surgery) | 0.154 | — | — | — | 0.001 | 1.453 | 0.700–3.559 | 0.131 |
| Preoperative steroids for ≥ 3 months | 0.007 | 1.843 | 1.007–1.906 | 0.045 | <0.001 | 2.166 | 1.106–3.569 | 0.036 |
| Enteral nutrition | 0.068 | 0.806 | 0.563–1.164 | 0.217 | 0.088 | 0.837 | 0.605–1.294 | 0.382 |
| Total colectomy | 0.032 | 2.455 | 1.399–4.013 | 0.173 | 0.023 | 1.963 | 1.562–3.223 | 0.096 |
| First time operation | 0.018 | 0.968 | 0.704–1.996 | 0.806 | 0.257 | — | — | — |
CD = crohn’s disease; UC = ulcerative colitis; OR = odds ratio; mGPS = modified Glasgow Prognostic Score.
Correlation between postoperative complications and mGPS.
| CD (n = 186) | UC (n = 84) | |||||||
|---|---|---|---|---|---|---|---|---|
| mGPS = 0 | mGPS = 1 | mGPS = 2 | P | mGPS = 0 | mGPS = 1 | mGPS = 2 | P | |
| No. of patients* | 101 (54.30%) | 53 (28.49%) | 32 (17.20%) | 29 (34.52%) | 44 (52.38%) | 11 (13.10%) | ||
| All complications* | 34 (33.66%) | 31 (58.49%) | 22 (68.75%) | <0.001 | 8 (27.59%) | 18 (40.91%) | 8 (72.73%) | 0.034 |
| Mild complications (Grade I–II)*‡ | 31 (30.69%) | 26 (49.06%) | 19 (59.36%) | 0.006 | 7 (24.14%) | 12 (27.27%) | 6 (54.55%) | 0.149 |
| Major complications (Grade III or greater)*‡ | 4 (3.96%) | 9 (16.98%) | 8 (25.00%) | 0.001 | 1 (3.45%) | 7 (15.91%) | 5 (45.45%) | 0.007 |
| Grade III*‡ | 4 (3.96%) | 7 (13.21%) | 9 (28.13%) | 1 (3.45%) | 6 (13.64%) | 3 (27.27%) | ||
| Abdominal-pelvic abscess | 2 (1.98%) | 3 (5.66%) | 3 (9.38%) | 1 (3.45%) | 2 (4.55%) | 2 (18.18%) | ||
| Pleural effusion | 0 | 1 (1.89%) | 2 (6.25%) | 0 | 1 (2.27%) | 0 | ||
| Anastomotic leakage | 1 (0.99%) | 1 (1.89%) | 3 (9.38%) | 0 | 1 (2.27%) | 0 | ||
| Gastrointestinal bleeding | 0 | 0 | 1 (3.13%) | 0 | 2 (4.55%) | 1 (9.09%) | ||
| Intra-abdominal bleeding | 0 | 1 (1.89%) | 1 (3.13%) | 0 | 0 | 0 | ||
| Stoma complications | 1 (0.99%) | 1 (1.89%) | 1 (3.13%) | 0 | 0 | 0 | ||
| Grade IV*‡ | 0 | 2 (3.77%) | 3 (9.38%) | 0 | 1 (2.27%) | 2 (18.18%) | ||
| Septic shock | 0 | 0 | 1 (3.13%) | 0 | 0 | 0 | ||
| Sepsis | 0 | 1 (1.89%) | 0 | 0 | 0 | 0 | ||
| Respiratory failure | 0 | 0 | 1 (3.13%) | 0 | 1 (2.27%) | 0 | ||
| Kidney failure | 0 | 1 (1.89%) | 1 (3.13%) | 0 | 0 | 1 (9.09%) | ||
| MODS | 0 | 0 | 0 | 0 | 0 | 1 (9.09%) | ||
| Grade V*‡ | 0 | 0 | 1 (3.13%) | 0.170 | 0 | 0 | 1 (9.09%) | 0.115 |
| SSI (+)* | 8 (7.92%) | 12 (22.64%) | 13 (40.63%) | 0.006 | 1 (3.45%) | 6 (13.64%) | 4 (36.36%) | 0.003 |
| Hospital stay (days)† | 17.19 ± 4.15 | 18.59 ± 4.25 | 20.26 ± 3.49 | 0.001 | 21.81 ± 3.66 | 24.98 ± 3.41 | 26.83 ± 4.78 | 0.001 |
CD = crohn’s disease; UC = ulcerative colitis; MODS = multiple organ dysfunction syndrome; SSI = surgical site infection.
*Values are expressed as the mean ± SD; †values are expressed as n (%); ‡Clavien-Dindo’s classification of surgical complication.
Validation and optimization of the mGPS in predicting postoperative complications.
| CD (n = 186) | UC (n = 84) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No. (%) | OR (95% CI) | P | AUC | No. (%) | OR (95% CI) | P | AUC | ||
| mGPS | 0 | 101 (54.30%) | 1 (reference) | <0.001 | 0.769 | 29 (34.52%) | 1 (reference) | <0.001 | 0.724 |
| 1 | 53 (28.49%) | 2.72 (1.35–4.89) | 29 (34.52%) | 1.48 (1.16–3.34) | |||||
| 2 | 32 (17.20%) | 3.94 (2.08–6.91) | 26 (30.95%) | 3.64 (1.85–5.77) | |||||
| mGPS | 0 | 91 (48.92%) | 1 (reference) | <0.001 | 0.830 | 28 (33.33%) | 1 (reference) | <0.001 | 0.821 |
| +Neutrophil ratio >75% | 1 | 60 (32.26%) | 2.30 (1.11–3.86) | 27 (32.14%) | 1.51 (1.09–2.73) | ||||
| 2 | 25 (13.44%) | 4.25 (1.96–7.54) | 12 (14.29%) | 3.99 (1.53–5.47) | |||||
| 3 | 10 (5.38%) | 11.86 (6.48–17.49) | 17 (20.24%) | 9.47 (5.24–15.33) | |||||
CD = crohn’s disease; UC = ulcerative colitis; OR = odds ratio; AUC = area under the curve; mGPS = modified Glasgow Prognostic Score.
Figure 2Receiver operating characteristic curves (ROC) for mGPS and mGPS + neutrophil ratio >75% in the prediction of postoperative complications. (A) For CD patients, the area under the receiver operating characteristic curve (AUC) for mGPS was 0.769, and AUC for mGPS + neutrophil ratio >75% was 0.830. (B) For UC patients, the AUC for mGPS was 0.724, and AUC for mGPS + neutrophil ratio >75% was 0.821.